Triomics Raises $22M Series B as Oncology AI Moves From Hype to Workflow

Healthcare has no shortage of data. It has a shortage of time. Triomics, a New York-based oncology AI company, announced a $22M Series B led by Battery Ventures, with participation from Nexus Venture Partners, Lightspeed, Y Combinator, Oncology Ventures, and Precision Health Informatics. The financing brings the company's total funding to more than $36M and will be used to accelerate adoption across health systems, oncology networks, and life sciences organizations. Founded in 2021 by Sarim Khan, Co-Founder and CEO, and Hrituraj Singh, Co-Founder and CTO, Triomics was built around a specific challenge facing cancer care organizations: extracting meaningful clinical intelligence from increasingly complex patient records. The announcement reflects growing investor confidence in oncology AI, a specialized segment of healthcare AI focused on clinical workflows, research operations, patient identification, and decision support.

The funding matters because oncology sits at the center of 1 of healthcare's largest operational problems: information overload. Cancer care generates enormous volumes of clinical notes, pathology reports, treatment histories, biomarker data, and research information. The challenge is no longer collecting data. The challenge is turning it into action before the opportunity to act disappears.

What Happened

Triomics raised a $22M Series B round led by Battery Ventures. Existing investors Nexus Venture Partners, Lightspeed, and Y Combinator returned, while Oncology Ventures and Precision Health Informatics joined as strategic investors. The round pushed total capital raised beyond $36M. Founded by Sarim Khan and Hrituraj Singh, Triomics focuses exclusively on oncology workflows. Rather than building a broad healthcare platform and searching for use cases later, the company chose 1 of the most data-intensive specialties in medicine and built around its unique challenges.

The company's platform supports clinical trial matching, visit preparation, and data curation through products including PRISM, Symphony, and Harmony. The objective is straightforward: help healthcare teams transform large volumes of unstructured clinical information into usable insights. That sounds simple until you remember what modern oncology actually looks like. A single patient journey can span years of treatment records, physician notes, pathology reports, imaging studies, biomarker testing, and clinical research activity. Healthcare organizations are not struggling because they lack information; they are struggling because critical information is often buried beneath everything else.

Why This Matters

Every industry eventually discovers that data accumulation and decision-making are not the same thing. Healthcare may be learning that lesson more painfully than most. Industry estimates suggest that roughly 80% of healthcare data exists in unstructured formats, creating significant challenges for clinical workflows, research programs, patient recruitment, and care coordination. The healthcare sector spent years digitizing information and is now entering a phase where extracting value from that information matters just as much as collecting it.

Triomics is part of a broader wave of oncology AI companies attempting to solve the operational consequences of digitization. The company's focus on oncology is particularly notable because cancer care represents 1 of the most complex information environments in medicine. Clinical trial matching illustrates the challenge. Identifying eligible patients often requires reviewing extensive records, treatment histories, biomarker profiles, and trial criteria, a process that can consume substantial time and resources even within leading cancer centers.

Healthcare organizations increasingly rely on resources like the National Cancer Institute, ClinicalTrials.gov, and the American Society of Clinical Oncology to support research and treatment initiatives. The ability to connect information across these environments is becoming increasingly valuable. AI's promise in healthcare has always sounded compelling, but investors increasingly appear interested in companies solving specific workflow problems rather than offering broad promises about artificial intelligence transforming everything. Triomics fits that emerging pattern.

Market Context

The funding arrives as healthcare AI moves from experimentation toward operational deployment. The conversation around AI changed dramatically over the past 2 years. Early discussions focused on model capabilities, while today's conversations focus on measurable outcomes, workflow integration, adoption, governance, and return on investment. That shift matters because healthcare organizations face mounting pressure to improve efficiency while managing growing volumes of clinical information.

Cancer centers are balancing increasingly complex treatment pathways, expanding research initiatives, workforce constraints, and rising patient expectations. This is where oncology AI is beginning to attract serious investor attention. Specialized platforms built for specific clinical environments are increasingly competing against broad, horizontal approaches, making domain expertise a competitive advantage rather than a nice-to-have feature. The Triomics funding round reflects that broader reality, with investors increasingly backing vertical AI companies positioned between expanding data complexity and the professionals responsible for navigating it.

Competitive Landscape

The healthcare AI market has become crowded. Nearly every week introduces another company promising to improve workflows, automate documentation, or unlock insights from medical records. The difference is specialization. Many healthcare AI companies pursue broad use cases across multiple specialties, while Triomics concentrated specifically on oncology.

That decision creates advantages and limitations. Specialization narrows the addressable market compared with general-purpose healthcare platforms, but it also creates deeper expertise, stronger domain knowledge, and products designed around the realities of oncology teams rather than generic healthcare assumptions. The return participation from Nexus Venture Partners, Lightspeed, and Y Combinator suggests existing stakeholders continue to see value in that approach, while Battery Ventures leading the round reinforces the view that specialized healthcare infrastructure remains an attractive investment category.

Precision Health Informatics adds another layer of strategic significance. As a subsidiary of Texas Oncology, 1 of the largest oncology care networks in the United States, the investment provides validation from an organization operating at the front lines of cancer care delivery.

What This Signals

The Triomics financing signals something larger than a single company milestone. It reflects growing investor confidence in vertical AI. For years, technology markets favored horizontal platforms designed to serve multiple industries, but AI is increasingly creating opportunities for the opposite approach: highly specialized systems built around deep domain expertise.

Healthcare represents fertile ground for that trend because context matters enormously. An oncology AI platform faces challenges that differ substantially from platforms designed for finance, cybersecurity, logistics, or legal workflows. Industry-specific knowledge increasingly looks less like a competitive advantage and more like a requirement. Triomics is part of a broader movement toward AI companies that understand a profession deeply rather than simply applying generic models to specialized environments.

The Bigger Industry Shift

Healthcare's next chapter may not be defined by who collects the most information. It may be defined by who can operationalize it most effectively. The industry's digital transformation created unprecedented volumes of data, and the next phase focuses on extracting value from that information without increasing complexity for clinicians, researchers, and administrators.

That is where companies like Triomics are positioning themselves. The company's new funding will support expansion across health systems, oncology networks, and life sciences organizations while growing AI, engineering, and forward-deployed teams. The larger takeaway is difficult to ignore: healthcare spent years building digital warehouses, and investors are now funding the companies trying to help people find what they need inside them.